US EditionKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
- Kodiak Sciences Inc. will present KSI-101 highlights at the 2025 Congress of the International Ocular Inflammation Society in Rio de Janeiro on June 27, 2025.
- KSI-101 is a first-in-class investigational bispecific biologic targeting interleukin-6 and VEGF for macular edema secondary to inflammation, a condition with significant treatment challenges.
- Dr. Pablo Velazquez-Martin stated, 'Managing macular edema secondary to inflammation today is challenging and represents an area of significant need for improvement in today's treatment approach.'
- Kodiak continues to enroll patients in the Phase 1b study called APEX to evaluate KSI-101's safety and tolerability.
Insights by Ground AI
Does this summary seem wrong?
27 Articles
27 Articles
All
Left
2
Center
13
Right
Hanford Sentinel+25 Reposted by 25 other sources
Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management along with key opinion…
Coverage Details
Total News Sources27
Leaning Left2Leaning Right0Center13Last UpdatedBias Distribution87% Center
Bias Distribution
- 87% of the sources are Center
87% Center
13%
C 87%
Factuality
To view factuality data please Upgrade to Premium
